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international assistance and coopera-
tion for access to essential medicines
Emily A. Mok
abstract 
Access to essential medicines is a critical problem that plagues many developing coun-
tries. With a daunting number of  domestic constraints — technologically, economi-
cally, and otherwise — developing countries are faced with a steep uphill battle to meet 
the human rights obligation of  providing essential medicines immediately. To meet 
these challenges, the international human rights obligations of  international assistance 
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access to essential medicines. This article seeks to highlight and expand upon the cur-
rent understanding of  international assistance and cooperation for access to essential 
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introduction
The problem of  access to medicines unduly burdens developing coun-
tries around the world. It has been estimated that “infectious diseases kill 
over 14 million people each year, nine out of  ten of  whom live in the 
developing world.”1 Children and young adults in Africa and Southeast 
Asia bear a heavy burden in infectious diseases, where half  of  the deaths 
among this group are due to six treatable diseases — HIV/AIDS (14% 
of  deaths), acute respiratory syndrome (11%), diarrheal diseases (11%), 
malaria (8%), measles (6%), and TB (2%).2 Despite the existence of  
effective medicines, millions of  people will continue to suffer and die 
needlessly from these and other life-threatening conditions because they 
cannot access the necessary treatments. It has been estimated that as 
many as two billion people (one-third of  the world’s population) lacks 
access to such essential medicines.3 
The stark inequities faced by such populations, notably those suffering 
from HIV/AIDS, have highlighted the acute need for international assis-
tance and cooperation in support of  their plight. Novel institutions have 
been established to provide assistance, such as UNAIDS; the Global 
Fund to Fight AIDS, Tuberculosis and Malaria; and the U.S. President’s 
Emergency Plan for AIDS Relief  (PEPFAR). Bold declarations of  
cooperation have emerged in a variety of  international policy fora. For 
example, World Trade Organization (WTO) member states issued a for-
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and implemented in a manner supportive of  WTO 
members’ right to protect public health, and in par-
ticular, to promote access to medicines for all.”4 This 
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ibilities,” such as compulsory licensing and parallel 
importation, to address public health concerns. 
Over the past decade, dramatic increases in access 
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have been achieved; however, the general problem 
of  access to medicines “for all” still persists.5 In the 
search for a solution, various scholars and health 
practitioners have turned to human rights in an effort 
to understand how greater access to medicines could 
be established through a rights-based approach in 
developing countries. A growing body of  work has 
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ative of  the right to health, outlines its component 
human rights obligations, considers its relationship 
with the competing interests of  intellectual prop-
erty rights, and analyzes its justiciability in domestic 
courts.6 There has been limited attention, however, 
to the extraterritorial obligations of  developed coun-
tries on this issue. Hence, one might ask: What 
international assistance and cooperation obligations 
do developed countries hold in relation to access to 
medicines, and how should it affect their policies and 
practices on this issue? Developed countries have a 
critical role in access to medicines efforts; yet, their 
support and response to this issue has been weaker 
than needed and, in some cases, counterproductive in 
the policy measures taken.
This article seeks to develop the current understand-
ing on international assistance and cooperation for 
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international assistance and cooperation for access 
to medicines by reviewing the derivation of  access 
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ments on international assistance and cooperation 
in international human rights law. The article then 
builds upon this knowledge to develop a set of  stan-
dards to guide developed country actions and policies 
in domestic and international fora. 
access to medicines as a human right
In order to establish conceptual clarity on the inter-
national assistance and cooperation obligations of  
states, it is necessary to understand the scope of  
access to medicines entitlements under international 
human rights law. The claim of  “access to medicines” 
has been used by developing countries, activists, inter-
governmental organizations, academics, and others 
in a variety of  contexts, but their use of  the phrase 
in relation to human rights does not always imply the 
same meaning. Quite often the phrase refers to treat-
ment access for life-threatening diseases that affect 
critical public health needs, or such treatment access 
in cases of  emergency, with a direct reference to the 
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medicines.”7 In other instances, the phrase includes 
the category of  “neglected diseases,” that is, diseases 
for which a lack of  attention has been paid toward 
research and development for appropriate treat-
ments.8 There has also been increasing reference to 
treatments for the chronic diseases and conditions, 
such as pain management and cancer.9 
The Universal Declaration of  Human Rights (UDHR), 
adopted in 1948 by the UN, proclaims in Article 25.1 
that “everyone has the right to a standard of  living 
adequate for the health of  himself  and of  his family, 
including food, clothing, housing and medical care.”10 
The term “medical care” as used by the UDHR is 
understood to include medicines — such as drugs 
and vaccines.11 Another key human rights source 
including access to medicines is the International 
Covenant on Economic, Social and Cultural Rights 
(ICESCR), which was adopted by the UN in 1966 
and holds the status of  an international treaty that is 
legally binding upon the 192 member states of  the 
UN. According to Article 12.1 of  the ICESCR, states 
must “recognize the right of  everyone to the enjoy-
ment of  the highest attainable standard of  physical 
and mental health.”12 Furthermore, in attaining the 

  
 	
> 
 @J@7	
 KL&L





X
	Y

for “the prevention, treatment and control of  epi-
demic, endemic, occupational and other diseases” 
and “the creation of  conditions which would assure 
to all medical service and medical attention in the 
event of  sickness.”13
To assist states with their implementation of  the 
ICESCR, the Committee on Economic, Social and 
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Comment No. 14.14 For example, the CESCR has 
interpreted Article 12 to indicate that the provision of  
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Programme on Essential Drugs” is a core obligation 
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of  states under the right to health.15 The World Health 
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“those that satisfy the priority health care needs of  the 
population.”16 To help guide countries in their selec-
tion and coverage of  medicines under national policies, 
WHO develops a biennial “model list” of  essential 
medicines.17 WHO recommends that these medicines 
“be available within the context of  functioning health 
systems at all times in adequate amounts, in the appro-
priate dosage forms, with assured quality and adequate 
information, and at a price the individual and the 
community can afford.”18 In recognition of  differing 
national health needs, WHO intends for “the concept 
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to many different situations; exactly which medicines 
are regarded as essential medicines remains a national 
responsibility.”19
The distinction between essential medicines — 
which are a core obligation — and other medicines 
is important for the explication of  state obligations. 
Brigit Toebes explains that core obligations must be 
guaranteed “immediately” and “under any circum-
stances.”20 Given that such obligations are considered 
to “encompass the essence of  the right,” it is criti-
cal to ensure its existence within a state or else the 
	
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
&21 This contrasts with 
other non-core obligations of  the right to health that 
are subject to “progressive realization,” which only 
require “deliberate, concrete and targeted” steps in 
an expeditious and effective manner.22 Such non-core 
obligations would include the other medicines that are 
not considered “essential” or have yet to exist. Hence, 
as Paul Hunt and Rajat Khosla conclude, “while a 
state is required to progressively realize access to non 
essential medicines, it has a core obligation of  imme-
diate effect to make essential medicines available and 
accessible throughout its jurisdiction.”23
The core obligation of  access to essential medicines, 
however, can often pose a serious problem for develop-
ing countries. In such countries, the large populations 
of  impoverished and disease-stricken individuals who 
lack basic necessities (such as food, water, and shelter) 
already cause a major strain on government resources, 
among other domestic economic and social concerns. 
In recognition of  the disparate realities amongst the 
countries, General Comment 14 states:
For the avoidance of  any doubt, the 
Committee wishes to emphasize that 
it is particularly incumbent on States 
parties and other actors in a position 
to assist, to provide “international 
assistance and cooperation, especially 
economic and technical” which enable 
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and other obligations.24
This comment emphasizes that human rights duties are 
not limited to domestic borders, but also encompass 
those that fall outside state jurisdiction. If  an industri-
alized nation were to disregard this, the nation could 
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legal obligations towards the right to health.”25 
The remainder of  this paper focuses largely on the 
core obligation of  access to essential medicines in 
order to explicate developed countries’ international 
assistance and cooperation duties. While it will touch 
upon the broader concept of  access to medicines, in 
the interest of  space, a detailed exploration of  these 
various dimensions would require a separate study. 
The following section elaborates on how internation-
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under international human rights law.
international assistance and 
cooperation according to international 
human rights law
The state obligation to provide international assis-
tance and cooperation has long been an area of  
debate among academics. While some might hold fast 
to the notion of  state sovereignty and the idea that 
states hold human rights obligations only in relation 
to their own citizens, the impacts of  globalization 
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boundaries. In addition, some argue that state obli-
gations of  international assistance and cooperation 
were intended by the drafters of  international human 
rights laws, as the obligation can be found in the key 
documents, including Articles 1(3), 55 and 56 of  the 
UN Charter; Articles 22 and 28 of  the UDHR; and 
Articles 2(1), 11(1), 11(2), 15(4), 22 and 23 of  the 
ICESCR. Sigrun Skogly believes that, because these 
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rarely been invoked, there is a need to “rediscover or 
uncover these obligations” from the body of  interna-
tional human rights law.26
For example, an important source of  international 
assistance and cooperation is found in Article 2(1) 
mok
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of  the ICESCR, which requires “[e]ach State Party 
to the present Covenant undertakes to take steps, 
individually and through international assistance and 
cooperation, especially economic and technical, to the 
maximum of  its available resources.”27 The “elusive 
and complex” nature of  this statement, which can 
be attributed to diplomatic negotiations, was noted 
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Comment No. 3 on “[t]he nature of  states parties’ 
obligations.”28 General Comment No. 3 explained 
that those who drafted the ICESCR intended that 
the statement, “to the maximum of  its available 
resources,” apply not only to the resources within a 
state, but also to “those available from the interna-
tional community through international cooperation 
and assistance.”29 
Yet, in what manner should developed countries assist 
and cooperate? To address this question, the tripar-
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on the developed country duty of  international assis-
tance and cooperation in greater detail.30 The duty 
to respect, which has been called a “classic” human 
rights obligation, refers to the requirement that states 
“avoid measures that hinder or prevent the enjoyment 
of  … rights in another state.”31 Such measures would 
include a state’s foreign policies and any aspects that 
might interfere with the realization of  rights outside of  
the state. The duty to protect requires that states take 
account of  human rights in their actions as members 
of  international organizations, as well as when entering 
into bilateral and multilateral agreements.32 It also calls 
upon states to “take measures to prevent non-state 
entities under their jurisdiction from interfering with 
the enjoyment of  the … rights abroad.”33 Such non-
state entities include private corporations that reside 
within their national jurisdiction but operate interna-
tionally or have an impact on other states, and mea-
sures to prevent them can take the form of  domestic 
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positive steps by facilitating, providing, and promot-
ing human rights in other states.34 This particular duty 
has been considered controversial, given its emphasis 
on positive state action in other countries, but is gain-
ing acceptance in the human rights community as a 
“secondary or subsidiary obligation [that] … applies 
if  the domestic state for reasons beyond its control 
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when “measures taken to respect and protect are not 
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obligations of international 
assistance and cooperation in relation 
to access to medicines 
In light of  the above summary, it is apparent that 
developed countries hold obligations of  internation-
al assistance and cooperation for access to essential 
medicines. Yet, despite the allusions to these top-
ics in international human rights law, there contin-
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international roles and responsibilities that should 
be met by states extraterritorially. This issue has 
prompted numerous authoritative, but nonbind-
ing, interpretative statements that aim to clarify and 
expand upon references to essential medicines in 
international agreements, especially given emerg-
ing global health trends and issues. Such statements 
include the UN Committee on Economic, Social 
and Cultural Rights General Comment 14, the UN 
Commission on Human Rights Resolution 2003/29, 
World Health Assembly Resolution WHA55.14, 
the UN Millennium Development Goals, Montreal 
Statement on Essential Medicines as a Human Right, 
WTO Declaration on the Agreement on Trade-
Related Aspects of  Intellectual Property Rights and 
Public Health, and the reports of  the UN Special 
Rapporteur on the Right to Health.36
The guidance offered by these sources is synthesized 
to develop a single, more coherent set of  interna-
tional standards for developed countries on access 
to essential medicines. The theme of  international 
assistance and cooperation as a duty, a theme found 
across almost all interpretative guidance on access 
to medicines, presents a critical set of  standards for 
developed countries. By applying the comprehensive 
guidelines listed in the CESCR’s General Comment 
No. 14 as a foundation, the discussion below details 
the international assistance and cooperation stan-
dards that developed countries must address.
To respect access to essential medicines in other countries, 
and to prevent others (that is, third parties) from 
violating this right 37 
This is a critical standard which obligates states “to 
refrain from interfering directly or indirectly” with 
a developing country’s efforts to achieve access to 
essential medicines.38 At the same time, it asks indus-
trialized nations to “protect” access to essential medi-
cines in developing countries by preventing third 
parties (such as pharmaceuticals or other countries) 
that may interfere with this fundamental component 
volume 12, no. 1 	
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of  the right to health.39 Such guidance is critical in 
understanding industrialized nation obligations in 
regards to the WTO TRIPS Agreement. 
According to the Doha Declaration on TRIPS and 
Public Health, developing countries have the right 
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their public health needs. First, countries have “the 
right to grant compulsory licenses and the freedom 
to determine the grounds upon which such licenses 
are granted.”40 Second, countries’ “practices relating 
to parallel importation cannot be challenged under 
the WTO dispute settlement system [and] … each 
Member is free to establish its own regime [for the 
use of  parallel importation] … without challenge.”41 
Hence, industrialized nations should refrain from 
interfering in developing country activities to apply 
compulsory licensing or parallel importation for 
access to essential medicines. Historically, the US has 
placed countries that attempt to exercise compulsory 
licensing on the US Trade Representative Watch List, 
known as the Special 301. This practice would effec-
tively pressure US trading partners, especially devel-
oping countries, into acting in accordance with US 
preferences in order to gain or maintain a favorable 
trading position with the US. Furthermore, industri-
alized nations should prevent others (for example, 
pharmaceutical companies) from interfering in such 
activities as well.
To facilitate access to essential medicines in other 
countries, whenever possible, and to provide the necessary 
aid in times of  emergency 42
In recognition of  the limitations of  developing 
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(for example, access to essential medicines) to their 
populations, it follows that an associated interna-
tional assistance and cooperation duty calls upon 
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in those countries. Furthermore, in situations of  
emergency, it is emphasized that developed countries 
have a responsibility to contribute to “the maximum 
of  [their] capacities.”43 The CESCR notes that other 
countries’ emergencies are a “collective responsibil-
ity” at an international level because “some diseases 
are easily transmissible beyond the frontiers of  a 
State.”44 Though General Comment No. 14 does not 
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gency, other international guidance has stated that 
countries have “the right to determine what consti-
tutes a national emergency or other circumstances of  
extreme urgency” and that such cases can be under-
stood to include “HIV/AIDS, tuberculosis, malaria 
and other epidemics.”45 
To ensure that access to essential medicines is granted 
due attention in international agreements and to 
consider the development of  further legal instruments 46
Industrialized nations are urged “to develop and 
implement national strategies,” including legal mea-
sures, that “safeguard or promote” access to essential 
medicines.47 Though many States have acceded to 
numerous international agreements recognizing obli-
gations to assist and cooperate in the provision of  
access to medicines, such agreements are often not 
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ignored and often relegated to rhetoric. This is a stan-
dard that requires greater attention and evaluation.
To ensure that no international agreement or policy 
adversely impacts upon access to essential medicines 48
As parties to numerous current international agree-
ments, as well as potential future agreements, states 
need to ensure that no adverse measures within the 
agreements will hinder access to essential medicines. 
Furthermore, states should never apply restrictions 
on the supply of  essential medicines in another state 
as a tool of  political or economic pressure – such 
as embargoes, political or theological ideology, or 
other similar measures.49 This has been an issue for 
a number of  developed countries and their tendency 
for corporate protectionism through the creation of  
“TRIPS-plus” provisions (that is, measures that go 
beyond what is required by TRIPS) in bilateral and 
regional trade agreements with developing countries. 
To ensure (by way of  membership) that the actions of  
international organizations take due account of  access 
to essential medicines 50
International organizations, such as the World Health 
Organization, the World Trade Organization, and the 
World Bank, play critical roles in setting policy and 
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access to medicines in developing countries. States 
can use their membership status within these interna-
tional organizations to ensure that access to essential 
medicines is properly accounted for in the activities 
of  such organizations. For instance, the WTO’s activ-
ities in setting minimum standards for the protection 
of  intellectual property rights (that is, Agreement 
on Trade-Related Aspects of  Intellectual Property 
mok
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countries’ access to medicines. Member states have 
worked to ensure that TRIPS address the issue of  
access to medicines through a subsequent clarifying 
statement known as the Declaration on the TRIPS 
agreement and public health.
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of  responsibilities in access to essential medicines by 
other actors 51
Though states possess primary accountability for the 
right to health, the General Comment also empha-
sizes that “all members of  society” possess certain 
“responsibilities towards the realization of  the right 
to health.”52 In the case of  access to essential medi-
cines, other societal actors involved include inter-
governmental and nongovernmental organizations, 
health professionals, civil society organizations, and 
private industry. The CESCR notes that in order for 
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an obligation to “provide an environment which 
facilitates the discharge of  these responsibilities.”53 
For example, the US has a duty to create an equal 
opportunity for health professionals to participate 
on government advisory committees pertaining to 
essential medicines policies, which is a privilege that 
the pharmaceutical industry currently enjoys. 
conclusion
This article seeks to highlight and clarify the inter-
national assistance and cooperation obligations of  
developed countries in relation to access to essen-
tial medicines. While developing countries hold the 
“primary obligation” for ensuring access to essential 
medicines within their jurisdiction, there are times 
when they might not have the necessary resources 
available to support such an effort.54 This dilemma 
has prompted attention into the international obliga-
tions of  states to support access to essential medi-
cines. While international obligations in human rights 
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through foreign aid), there are also duties to respect 
and protect the realization of  access to essential med-
icines in other states. 
It is undoubtedly the case that international assis-
tance and cooperation standards for access to essen-
tial medicines exist, but the wide array of  authorita-
tive documentation from which they had to be drawn 
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acknowledge such standards. A review of  these vari-
ous aforementioned documents revealed an array of  
scattered agreements and declarations that pertain to 
state obligations, but also a general consistency in the 
expectations for international assistance and coop-
eration that are addressed most comprehensively by 
General Comment No. 14. Despite the general con-
sistency in the international expectations of  states, 
as illustrated in the synthesized set of  international 
standards, the scattered nature of  these standards 
amongst the various documents can allow states to 
conveniently “miss” or disregard certain obligations. 
Hence, for the purposes of  implementation, it would 
be best to present a single, coherent set of  standards 
from which states can report on or be criticized 
against and to promote comprehensive implementa-
tion by states.
The array of  authoritative guidance indicates a delib-
erate movement by the international order to crys-
tallize the elusive access to medicines obligations 
of  developed countries. The acceptance of  these 
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cant challenges due to its heavy basis on socioeco-
nomic rights. As Paul Hunt has noted, “[a]lthough 
the right to health is [a] fundamental human right, 
with the same international legal status as freedom of  
religion or the right to a fair trial, [it] is not as widely 
recognized as these other civil and political rights.”55 
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policy concerns (for example, international trade 
and development) may be granted special preference 
over access to medicines because of  their impact on 
national economic or security interests. 
To some degree, it would appear that developed 
countries are supporting access to medicines in other 
countries through their growing involvement in glob-
al health programs providing treatment. Such pro-
grams include multilateral initiatives (for example, the 
Global Fund) and bilateral programs (for example, 
the UK Department for International Development 
[DFID] and PEPFAR). Recent history has shown, 
however, that developed countries still need to 
remain cognizant of  their international assistance 
and cooperation obligations to respect, protect, and 
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organizations and in adopting multilateral, regional, 
or bilateral agreements. For example, the selective 
activities of  bilateral global health programs have 
sometimes shown a preference for recipient coun-
tries that provide a national security interest. In addi-
volume 12, no. 1 	
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critical concepts
http://www.who.int/medicines/areas/policy/
tripshealth.pdf.
5. J. Wise, “Access to AIDS medicines stumbles on 
trade rules,” Bulletin of  the World Health Organization 
84/5 (2006). Available at http://www.who.int/bul-
letin/volumes/84/5/news10506/en/index.html.
6. S. P. Marks, “Access to essential medicines as a 
component of  the right to health,” in A. Clapham 
and M. Robinson (eds), Realizing the right to heath, 
Swiss Human Rights Book 3 (Zurick: Rüffer & 
Rub, 2009), vol. 3, pp. 80–99. Available at http://
www.swisshumanrightsbook.com/SHRB/shrb_03_
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right to health enforceable through the courts?” 
Lancet 368/9532 (2006), pp. 305–311; Anand 
Grover, UN Special Rapporteur on the right of  
everyone to the enjoyment of  the highest attainable 
standard of  physical and mental health, Report to 
the UN General Assembly Human Rights Council, 
UN Doc. No. A/HRC/11/12 (2009). Available at 
http://www.unhcr.org/refworld/docid/49faf7652.
html; H. V Hogerzeil, “Essential medicines and hu-
man rights: What can they learn from each other?” 
Bulletin of  the World Health Organization 84/5 (2006), 
pp. 371–375. Available at http://www.who.int/bul-
letin/volumes/84/5/371.pdf; P. Hunt and R. Kho-
sla, “The human right to medicines,” Sur-International 
Journal on Human Rights 5/8 (2008), pp. 101–121; 
P. Cullet, “Patents and medicines: The relationship 
between TRIPS and the human right to health,” 
International Affairs 79/1 (2003), pp. 139–160.
7. World Health Organization, Essential medicines 
(Geneva: World Health Organization, 2010). Avail-
able at http://www.who.int/medicines/services/
essmedicines_def/en/index.html.
8. P. Hunt, “Neglected diseases, social justice and 
human rights: Some preliminary observations,” United 
Nations Health and Human Rights Working Paper Series 1 
(Geneva: World Health Organization, 2003).
9. A. Thom, “Dying in pain a reality for most 
Africans,” Health-e (Nov. 16, 2009). Available 
at http://www.health-e.org.za/news/article.
php?uid=20032573; A. Taylor, L. O. Gostin, and K. 
Pagonis, “Ensuring effective pain treatment,” Journal 
of  the American Medical Association 299/1 (2008), pp. 
tion, bilateral programs have not always upheld non-
discrimination principles by neglecting vulnerable 
populations requiring treatment, such as sex work-
ers and men who have sex with men. States need to 
also develop ways to incorporate their international 
human rights commitments into their domestic and 
foreign policy strategies. This would allow states to 
account for international human rights interests in all 
government sectors and is especially important for 
access to medicines. For example, the UK recently 
launched a government policy strategy known as 
“Health is Global,” which aims to take the health of  
people beyond its borders into account.56 
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lating and incentivizing the pharmaceutical industry 
to pay greater attention to the medicines that are 
needed by developing countries. In terms of  existing 
medicines, the participation of  corporations in drug 
donation and discount programs are a critical factor 
in alleviating the problem of  medicines affordability 
in developing countries. Neglected diseases, however, 
will require the developed countries to implement 
incentive schemes that would attract the pharmaceu-
tical industry to invest their R&D resources for new 
or improved medicines. The current approaches have 
been weaker than needed, and states can do much to 
establish the enabling environment that would encour-
age industry participation in access to medicines.
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